Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study
Derek Conkle-Gutierrez, Calvin Kim, Sarah M. Ramirez-Busby, Samuel J. Modlin, Mikael Mansjö, Jim Werngren, Leen Rigouts, Sven Hoffner, Faramarz Valafar
Abstract
Point mutations in the rrs gene and the eis promoter are known to confer resistance to the second-line injectable drugs (SLIDs) amikacin (AMK), capreomycin (CAP), and kanamycin (KAN). While mutations in these canonical genes confer the majority of SLID resistance, alternative mechanisms of resistance are not uncommon and threaten effective treatment decisions when using conventional molecular diagnostics.
Topics & Concepts
Mycobacterium tuberculosisDrug resistanceTuberculosisBiologyGenome-wide association studyGeneticsDrugExtensively drug-resistant tuberculosisGenomeMicrobiologyVirologyMultiple drug resistanceMedicineGenotypeGenePharmacologySingle-nucleotide polymorphismPathologyTuberculosis Research and EpidemiologyMycobacterium research and diagnosisDiagnosis and treatment of tuberculosis